Source Genomics Expands Rapid Sanger Sequencing Services to the North of the UK
Cambridge, UK, 19 June 2023: Source Genomics, a part of the Source BioScience Group, today announced their genomic laboratory expansion into the North of the UK for increased capacity of its Sanger sequencing services leading to faster turnaround times for data delivery.
Well done to all six teams from Domainex who took on the 3 Peaks challenge to raise money for Tŷ Hafan! This amazing charity helps life-limited children in Wales to make the most of the time they have left together with their families.
There is still time to donate: https://www.justgiving.com/team/Domainex3peaks?invite=true
Bicycle Therapetuics and MRC Laboratory of Molecular Biology have shared a recent publication in Nature Communications describing the effectiveness of Bicycles as antivirals against SARS-CoV-2.
Read the full publication here: https://www.nature.com/articles/s41467-023-39158-1.epdf?sharing_token=MB...
Discover state-of-the-art Category II wet lab space, co-loacted with world experts in vaccines and stemcells at the Royal Veterinary College's (RVC) Centre for Vaccinology and Regenerative Medicine (CVRM) in the beautiful Hertfordshire countryside.
Read more: https://www.lbic.com/lbic-cvrm
17 June 2023
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women’s health, has announced the acquisition of the scientific assets of Imagen Therapeutics Limited from its appointed liquidators for £170,000.
UK pharmaceutical services company Imagen offered personalised cancer treatment through the collection and use of well-characterised, patient-derived cells.
• Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio.
• Agreement to utilize PrecisionLife’s combinatorial analytics platform to identify genetic biomarkers that will optimize patient selection across multiple CNS clinical trials.
AMSBIO is a leading provider of ready-to-use Adeno-Associated Virus (AAV) that can be engineered to efficiently deliver specific DNA sequences into target cells with a low immunogenicity.
Aptamer Group CTO, Dr David Bunka, will present at Neuro-Bio’s Science Day on Optimer technology and the development of binders to support the diagnostic